Literature DB >> 28516400

Systematic Investigation of the Role of Surfactant Composition and Choice of oil: Design of a Nanoemulsion-Based Adjuvant Inducing Concomitant Humoral and CD4+ T-Cell Responses.

Signe Tandrup Schmidt1,2, Malene Aaby Neustrup1, Stine Harloff-Helleberg1, Karen Smith Korsholm2, Thomas Rades1, Peter Andersen2, Dennis Christensen2, Camilla Foged3.   

Abstract

PURPOSE: Induction of cell-mediated immune (CMI) responses is crucial for vaccine-mediated protection against difficult vaccine targets, e.g., Chlamydia trachomatis (Ct). Adjuvants are included in subunit vaccines to potentiate immune responses, but many marketed adjuvants stimulate predominantly humoral immune responses. Therefore, there is an unmet medical need for new adjuvants, which potentiate humoral and CMI responses. The purpose was to design an oil-in-water nanoemulsion adjuvant containing a synthetic CMI-inducing mycobacterial monomycoloyl glycerol (MMG) analogue to concomitantly induce humoral and CMI responses.
METHODS: The influence of emulsion composition was analyzed using a systematic approach. Three factors were varied: i) saturation of the oil phase, ii) type and saturation of the applied surfactant mixture, and iii) surfactant mixture net charge.
RESULTS: The emulsions were colloidally stable with a droplet diameter of 150-250 nm, and the zeta-potential correlated closely with the net charge of the surfactant mixture. Only cationic emulsions containing the unsaturated surfactant mixture induced concomitant humoral and CMI responses upon immunization of mice with a Ct antigen, and the responses were enhanced when squalene was applied as the oil phase. In contrast, emulsions with neutral and net negative zeta-potentials did not induce CMI responses. The saturation degree of the oil phase did not influence the adjuvanticity.
CONCLUSION: Cationic, MMG analogue-containing nanoemulsions are potential adjuvants for vaccines against pathogens for which both humoral and CMI responses are needed.

Entities:  

Keywords:  adjuvant; drug delivery; emulsion; immune response; vaccine

Mesh:

Substances:

Year:  2017        PMID: 28516400     DOI: 10.1007/s11095-017-2180-9

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  33 in total

1.  Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes.

Authors:  Samuele Calabro; Marco Tortoli; Barbara C Baudner; Alessandra Pacitto; Mario Cortese; Derek T O'Hagan; Ennio De Gregorio; Anja Seubert; Andreas Wack
Journal:  Vaccine       Date:  2011-01-06       Impact factor: 3.641

Review 2.  Vaccine adjuvant formulations: a pharmaceutical perspective.

Authors:  Luis A Brito; Padma Malyala; Derek T O'Hagan
Journal:  Semin Immunol       Date:  2013-07-12       Impact factor: 11.130

3.  A statistically defined endpoint titer determination method for immunoassays.

Authors:  A Frey; J Di Canzio; D Zurakowski
Journal:  J Immunol Methods       Date:  1998-12-01       Impact factor: 2.303

4.  Vaccine adjuvant MF59 promotes retention of unprocessed antigen in lymph node macrophage compartments and follicular dendritic cells.

Authors:  Rocco Cantisani; Alfredo Pezzicoli; Rossella Cioncada; Carmine Malzone; Ennio De Gregorio; Ugo D'Oro; Diego Piccioli
Journal:  J Immunol       Date:  2015-01-14       Impact factor: 5.422

5.  Protection Against Chlamydia trachomatis Infection and Upper Genital Tract Pathological Changes by Vaccine-Promoted Neutralizing Antibodies Directed to the VD4 of the Major Outer Membrane Protein.

Authors:  Anja W Olsen; Frank Follmann; Karin Erneholm; Ida Rosenkrands; Peter Andersen
Journal:  J Infect Dis       Date:  2015-03-06       Impact factor: 5.226

Review 6.  The mechanism of action of MF59 - an innately attractive adjuvant formulation.

Authors:  D T O'Hagan; G S Ott; E De Gregorio; A Seubert
Journal:  Vaccine       Date:  2012-06-19       Impact factor: 3.641

7.  Adjuvant effects of sulfolipo-cyclodextrin in a squalane-in-water and water-in-mineral oil emulsions for BHV-1 vaccines in cattle.

Authors:  S A Romera; L A Hilgers; M Puntel; P I Zamorano; V L Alcon; M J Dus Santos; J Blanco Viera; M V Borca; A M Sadir
Journal:  Vaccine       Date:  2000-08-15       Impact factor: 3.641

8.  Influence of type of oil and surfactant concentration on the efficacy of emulsified Mycobacterium bovis BCG cell walls to induce tumor regression in guinea pigs.

Authors:  E Yarkoni; H J Rapp
Journal:  Infect Immun       Date:  1980-06       Impact factor: 3.441

9.  Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements.

Authors:  Else Marie Agger; Ida Rosenkrands; Jon Hansen; Karima Brahimi; Brian S Vandahl; Claus Aagaard; Kerstin Werninghaus; Carsten Kirschning; Roland Lang; Dennis Christensen; Michael Theisen; Frank Follmann; Peter Andersen
Journal:  PLoS One       Date:  2008-09-08       Impact factor: 3.240

10.  Intramuscular Priming and Intranasal Boosting Induce Strong Genital Immunity Through Secretory IgA in Minipigs Infected with Chlamydia trachomatis.

Authors:  Emma Lorenzen; Frank Follmann; Sarah Bøje; Karin Erneholm; Anja Weinreich Olsen; Jørgen Steen Agerholm; Gregers Jungersen; Peter Andersen
Journal:  Front Immunol       Date:  2015-12-16       Impact factor: 7.561

View more
  1 in total

1.  Induction of Cytotoxic T-Lymphocyte Responses Upon Subcutaneous Administration of a Subunit Vaccine Adjuvanted With an Emulsion Containing the Toll-Like Receptor 3 Ligand Poly(I:C).

Authors:  Signe Tandrup Schmidt; Gabriel Kristian Pedersen; Malene Aaby Neustrup; Karen Smith Korsholm; Thomas Rades; Peter Andersen; Camilla Foged; Dennis Christensen
Journal:  Front Immunol       Date:  2018-04-30       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.